Compare Globus Medical Inc. Class A Common Stock (GMED) vs InMode Ltd (INMD) Price & Performance

Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.

GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.

InMode (INMD) trades at $14.305, showing minimal daily movement with a 0.03% gain. The stock maintains a bullish technical signal despite mixed indicators, with RSI suggesting mild overbought conditions. Fundamentally, the company demonstrates strong profitability with 76.52% gross margins and 20.69% net income margins, though 2026 guidance shows potential margin compression. Recent developments include the launch of Morpheus8 Cool technology and an unsolicited acquisition offer from Steel Partners at $16.75 per share in July 2026.

The investment outlook balances attractive valuation metrics (P/E of 11.83, EV/EBITDA of 4.68) against cyclical industry headwinds and management capital allocation concerns. Analyst sentiment is divided with 45% buy ratings, while technicals suggest near-term consolidation around current levels. Key risks include US platform sales decline and execution on international growth strategy.